<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841828</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2006-14</org_study_id>
    <secondary_id>Nº EudraCT 2007-007031-13</secondary_id>
    <nct_id>NCT00841828</nct_id>
  </id_info>
  <brief_title>Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients</brief_title>
  <official_title>A Phase II Randomised, Multicentre Compare Epirubicine and Cyclophosphamide Treatment Plus Docetaxel and Trastuzumab Versus Epirubicine and Cyclophosphamide Treatment Plus Docetaxel and Lapatinib in Women With Primary Resectable Breast Cancer or Locally Advanced Breast Cancer Positive Her 2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II randomized multicenter Trial to compare Epirubicine and Cyclophosphamide plus
      Docetaxel and Trastuzumab with Epirubicine and Cyclophosphamide plus Docetaxel and Lapatinib
      for patients with positive HER2 neu and resectable breast cancer or locally advanced breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete pathological response Rate</measure>
    <time_frame>Within 3-4 weeks after last docetaxel dose, surgery will be performed to evaluate pathological response</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity assessment</measure>
    <time_frame>After each treatment cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EC -&gt; T + Lapatinib
Drugs plus Biological</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EC -&gt; T + Trastuzumab
Drug plus Biological</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, Cyclophosphamide, Taxotere, Herceptín, Lapatinib</intervention_name>
    <description>- EC (each 21 days for 4 cycles) -&gt; T + lapatinib (each 21 days for 4 cycles) vs
EC (each 21 days for 4 cycles) -&gt; T + herceptin (each 21 days for 4 cycles)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signature of the written informed consent.

          2. Histological documentation of breast cancer.

          3. Stage I (T1, N0M0), IIA (T2N0M0); IIB (T2N1M0, T3N0M0), IIIA (TXN2M0) and IIIB
             (T3N1M0, T4NXM0) primary resectable breast cancer or locally advanced breast cancer.

          4. HER2-positive breast cancer, defined as IHC 3+ or positive FISH. When IHC 2+ HER2
             status must be assessed by FISH.

          5. The patient granted her consent for taking a biopsy before treatment

          6. The patient granted her consent for sending two tumor samples to central laboratory
             for molecular sub study.

          7. Two weeks prior randomization pregnancy test negative for women of childbearing
             potential.

          8. Women of childbearing potential must use adequate contraceptive measures during
             participation into study. Oral, injectable or implant hormonal contraceptives measure
             are not permitted.

          9. A WHO performance status of 0 or 1 ( Karnofsky ³ 80)

         10. Age &gt; 18 years.

         11. Absence of metastases disease

         12. Baseline EKG 12 weeks prior to randomization. Baseline LVEF value within limit of
             normal value for the institution or &gt; 50% of basal value

         13. Normal laboratory test 2 weeks prior to randomization Haematology values: Neutrophil
             count ≥ 1,5 x109/l; Platelets ≥ 100 x 109/l; Haemoglobine ≥ 10mg/dl Biochemistry
             values: serum total bilirubin £ 1 ULN; ASAT (SGOT) y ALAT (SGPT) £ 2,5 ULN; alkaline
             phosphatase £ 5 ULN. The patients which ASAT and/or ALAT value are &gt; 1,5 ULN along
             with alkaline phosphatase value &gt; 2,5 ULN will be not included into the study.

             Renal function: serum creatinine £ 175 µmol/l (2 mg/dl). If the value are borderline,
             clearance creatinine must be ≥ 60 ml/min

         14. 12 weeks prior to randomization the following assessments and procedures must be
             fulfilled: Bilateral mammography; MRI Breast and axillary; Chest X-Ray (PA and
             lateral); Abdominal ultrasound; Chest CT-Scan; Abdominal CT-Scan. Bone Scan (if
             applicable)

         15. Patients must be accessible for treatment and follow up

        Exclusion Criteria:

          1. Patients with lumpectomy, partial mastectomy, modified radical mastectomy are not
             allowed to include into study.

          2. Prior Immunotherapy, hormonal therapy and chemotherapy for breast cancer is not
             allowed.

          3. Prior therapy with anthracycline and taxanes ( paclitaxel and docetaxel) is not
             permitted for any neoplasia.

          4. Prior radiotherapy for breast cancer.

          5. Bilateral invasive breast carcinoma

          6. Pregnant or nursing patients. Negative pregnant test ( serum or urine) 14 days prior
             to randomization.

          7. HER 2 negative breast cancer

          8. Patients of childbearing potential must be use adequate contraceptive measures during
             study treatment. No hormonal contraceptive measure is permitted.

          9. Any M1 breast cancer

         10. Any motor or sensorial neurotoxicity grade ≥ 2 according to CTC criteria version 3.

         11. Serious cardiac illness or medical conditions: Congestive heart failure, angina
             pectoris requiring specific treatment, myocardial infarction 1 year prior to enroll in
             the study; poorly controlled hypertension or high-risk uncontrolled arrhythmias.

             History of significative neurological or psychiatric disease ( psychotic, dementia or
             attack ) what is unable to patient to grant her informed consent.

             Uncontrolled severe Infection Uncontrolled diabetes mellitus, active peptic ulcer

         12. Current malignancy or previous malignancy other that breast cancer. Exception cell
             carcinoma of the skin no melanoma, carcinoma in situ of the cervix or any other cancer
             in the past 10 years.

         13. Long term treatment with corticoids except 6 months prior to inclusion in the study
             and low doses ( £ 20 mg metilprednisolone or equivalent )

         14. Corticoid use contraindication

         15. Concomitant hormonal replacement therapy. Previous treatment should be interrupted
             before inclusion into study.

         16. Cardiopathy what stops patient taking Docetaxel and Herceptin: myocardial infarction
             recorded; angina pectoris requiring specific treatment; any congestive heart failure
             recorded; arrhythmia grade 3 or 4 according to CTC ver.3; any relevant valvular
             disease; chest X ray which shows cardiomegaly or EKG which shows ventricular
             hypertrophy unless FEVI value has been upper URL in the last 3 months.

         17. Poorly controlled hypertension ( systolic &gt; 180 mm Hg or diastolic &gt; 100 mm Hg). The
             patients with controlled hypertension under treatment can be included into study

         18. Patients under treatment of arrhythmia, angina or congestive heart failure with drug
             which modifies cardiac conduction (after digital, beta blocker or inhibitors calcium
             channel) are excluded. However if these drugs are took for arterial tension the
             patient can be included into study.

         19. The patient must interrupt concomitant treatment with hormonal therapy ej. raloxifen,
             tamoxifen and selective estrogen receptor modulators (SERM) prior to randomization.

         20. Concomitant use of inhibitors and inductors of enzyme CYP3A4 complex ( ketoconazol,
             itraconazol or grape juice; rifampicin, carbamazepin or fenitoin ) are not permitted.
             Also, drug are substrate of enzyme CYP2C8 complex is not permitted along with
             lapatinib treatment.

         21. Concurrent treatment with an investigational agent or participation in another
             therapeutic clinical trial within 30 days prior to randomization into study.

         22. Concomitant treatment with other anticancer therapy

         23. Hypersensitivity reaction to drugs herceptin, lapatinib or their excipients.

         24. Male
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Lluch, PhD., MD.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico de Valencia. Av. Blasco Ibáñez, 17. 46010 Valencia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilio Alba, PhD., MD.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Virgen de la Victoria. Campus de Teatinos, s/n. 29010 Málaga</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Albanell, PhD., MD.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital del Mar. Paseo Marítimo, 25-29. 08003 Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Badalona/Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xarxa Asistencial de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporación Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Espíritu Santo</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <state>Barcelona</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrasa</name>
      <address>
        <city>Tarrasa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrasa</name>
      <address>
        <city>Tarrasa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Cíes</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Yagüe</name>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico de Guipúzcoa</name>
      <address>
        <city>San Sebastián</city>
        <zip>20012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 28, 2014</submitted>
    <returned>May 27, 2014</returned>
    <submitted>July 6, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 22, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 9, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

